Literature DB >> 3779711

Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose.

S Duewell, W Horst, G Westera.   

Abstract

A monoclonal antibody (Tumak) against carcinoembryonic antigen (CEA) was injected into nude mice bearing a human colon carcinoma (Co-112). The tumor uptake was found to be dependent on the size of the tumors: relative uptake (percentage of the injected dose/gram tumor (% i.d./g) decreased for tumors with weights up to approximately 1 g, although the absolute uptake (% i.d./tumor) still increased over the same weight range. In the constant region (greater than or equal to 1 g) mean relative tumor uptake was approximately 4% i.d./g. The same tumor size dependence was found for the relative Tumak uptake in the other mouse organs studied (e.g., blood, liver, spleen and muscle). Consequently tumor/organ ratios were found to be independent of tumor size. Tumor uptake was also studied for various doses of Tumak (0.07-120 micrograms) in tumors of approximately 1 g. Evidence was found for a threshold dose of 0.1 microgram under which no serious tumor uptake appeared. From 1 to 120 micrograms no further dependence of Tumak distribution on applied dose was found: the relative uptake of all organs remained the same but the absolute uptake increased with dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779711     DOI: 10.1007/bf00199814

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

Review 1.  Monoclonal antibodies in nuclear medicine.

Authors:  A M Keenan; J C Harbert; S M Larson
Journal:  J Nucl Med       Date:  1985-05       Impact factor: 10.057

Review 2.  Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies.

Authors:  R H Begent
Journal:  Biochim Biophys Acta       Date:  1985

3.  In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts.

Authors:  M V Pimm; M J Embleton; A C Perkins; M R Price; R A Robins; G R Robinson; R W Baldwin
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

4.  Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies.

Authors:  F H DeLand; D M Goldenberg
Journal:  Semin Nucl Med       Date:  1985-01       Impact factor: 4.446

5.  Melanoma localization in nude mice with monoclonal Fab against p97.

Authors:  P L Beaumier; K A Krohn; J A Carrasquillo; J Eary; I Hellström; K E Hellström; W B Nelp; S M Larson
Journal:  J Nucl Med       Date:  1985-10       Impact factor: 10.057

6.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

7.  Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.

Authors:  R S Accolla; S Carrel; J P Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.

Authors:  J L Murray; M G Rosenblum; R E Sobol; R M Bartholomew; C E Plager; T P Haynie; M F Jahns; H J Glenn; L Lamki; R S Benjamin
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

9.  Radioimmunodetection of human tumor xenografts by monoclonal antibodies.

Authors:  D Herlyn; J Powe; A Alavi; J A Mattis; M Herlyn; C Ernst; R Vaum; H Koprowski
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Specific carcinoembryonic antigens of the human digestive system.

Authors:  P Gold; S O Freedman
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307

View more
  5 in total

1.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor.

Authors:  O C Boerman; R M Sharkey; G Y Wong; R D Blumenthal; R L Aninipot; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.

Authors:  G Westera; T Rülicke; A Smith; S Duewell
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

4.  Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer.

Authors:  M R Hamblin; M Del Governatore; I Rizvi; T Hasan
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

5.  Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.

Authors:  H Kobayashi; B F Sun; E S Han; M K Kim; N Le; Q C Wang; D L Nelson; I Pastan; T A Waldmann; C H Paik; J A Carrasquillo
Journal:  Jpn J Cancer Res       Date:  1998-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.